The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial.
 
Hirohito Tada
Honoraria - Chugai Pharma
 
Tetsuya Mitsudomi
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi-Sankyo; Ethicon; Guardant Health; Janssen Oncology; Kyowa Hakko Kirin; Lilly; Merck KGaA; Merck KGaA; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Thermofisher Scientific Biomarkers
Consulting or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; Lilly; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Thermo Fisher Scientific
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi/Aventis (Inst); Taiho Pharmaceutical (Inst)
 
Takeharu Yamanaka
Honoraria - Bayer; Chugai Pharma; Takeda
Research Funding - Bayer (Inst); Chugai Pharma (Inst); Taiho Oncology (Inst)
 
Kenji Sugio
No Relationships to Disclose
 
Masahiro Tsuboi
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Johnson & Johnson; Medtronic; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Boehringer Ingelheim (Inst); Merck (Inst)
 
Isamu Okamoto
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; MSD Oncology; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai/Roche (Inst); Lilly (Inst); MSD Oncology (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yasuo Iwamoto
No Relationships to Disclose
 
Noriaki Sakakura
No Relationships to Disclose
 
Shunichi Sugawara
Honoraria - AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Kyowa Kirin; Lilly; MSD K.K; Nippon Boehringer Ingelheim; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Yakult Honsha
 
Shinji Atagi
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Hisamitsu Pharmaceutical; Kyowa Hakko Kirin; Lilly Japan; Merck; MSD K.K; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Thermo Fisher Scientific
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Merck (Inst); MSD K.K (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Roche (Inst); Taiho Pharmaceutical (Inst)
 
Toshiaki Takahashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Chugai Pharma; Lilly Japan; MSD K.K.; Ono Pharmaceutical; Pfizer; Roche
Research Funding - AstraZeneca Japan (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); MSD K.K. (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst)
 
Hidetoshi Hayashi
Honoraria - AstraZeneca Japan; Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Merck Serono; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Pfizer; Shanghai HaiHe Pharmaceutical
Research Funding - Abbvie (Inst); AC Medical (Inst); Astellas Pharma (Inst); AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Associates Co., Ltd. (Inst); GlaxoSmithKline (Inst); Japan Clinical Research Operations (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical; Otsuka (Inst); PAREXEL (Inst); Pfizer (Inst); PPD-SNBL (Inst); Quintiles Inc. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Honsha (Inst)
Patents, Royalties, Other Intellectual Property - Sysmex
 
Morihito Okada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Covidien; CSL Behring; Johnson & Johnson; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihon Medi-Physics (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Hiroshige Yoshioka
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Delta-Fly Pharma; Kyowa Kirin Co., Ltd.; Lilly; MSD K.K; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Delta-Fly Pharma
 
Hidetoshi Inokawa
No Relationships to Disclose
 
Kazuhisa Takahashi
No Relationships to Disclose
 
Masahiko Higashiyama
No Relationships to Disclose
 
Ichiro Yoshino
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; Intuitive Surgical; Johnson & Johnson; Pfizer; Shionogi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Covidien/Medtronic; Intuitive Surgical
Research Funding - Chugai Pharma (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Kazuhiko Nakagawa
Honoraria - 3H Clinical Trial; Abbvie; Amgen; Amgen; AstraZeneca Japan; Bayer Yakuhin; Bristol-Myers Squibb; CareNet; Chugai Pharma; Kyorin; Kyowa Kirin Co., Ltd.; Lilly; Medical Mobile Communications; Medical Review Co., Ltd.; Merck; MSD K.K; Nikkei Business Publications, Inc; Nippon Boehringer Ingelheim; Nippon Boehringer Ingelheim; Nippon Kayaku; Novartis; Ono Pharmaceutical; Pfizer; Roche; Taiho Pharmaceutical; Takeda; YODOSHA
Consulting or Advisory Role - Kyorin; Lilly Japan; Ono Pharmaceutical; Pfizer
Research Funding - A2 Healthcare (Inst); Abbvie (Inst); AstraZeneca Japan (Inst); Bayer Yakuhin (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Covance (Inst); Covance (Inst); Daiichi Sankyo (Inst); Eisai (Inst); EPS Holdings (Inst); EPS International (Inst); GlaxoSmithKline K.K. (Inst); IQvia (Inst); Japan Clinical Research Operations (Inst); Kissei Pharmaceutical (Inst); Lilly (Inst); Medical Reserch Support (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); MSD K.K (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); PAREXEL International Corp. (Inst); Pfizer (Inst); Pfizer (Inst); PPD-SNBL (Inst); PRA HEALTHSCIENCES (Inst); Sanofi (Inst); SymBio Pharmaceuticals (Inst); Syneos Health (Inst); Sysmex (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)